Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
Garcia-Manero, Guillermo, Dr Prof, Fenaux, Pierre, Prof, Al-Kali, Aref, MD, Baer, Maria R, Prof, Sekeres, Mikkael A, Prof, Roboz, Gail J, Prof, Gaidano, Gianluca, Prof, Scott, Bart L, MD, Greenberg, Peter, Prof, Platzbecker, Uwe, Prof, Steensma, David P, MD, Kambhampati, Suman, MD, Kreuzer, Karl-Anton, Prof, Godley, Lucy A, Prof, Atallah, Ehab, MD, Collins, Robert, Prof, Kantarjian, Hagop, Prof, Jabbour, Elias, MD, Wilhelm, Francois E, MD, Azarnia, Nozar, PhD, Silverman, Lewis R, MD
Published in The lancet oncology (01.04.2016)
Published in The lancet oncology (01.04.2016)
Get full text
Journal Article